Levetiracetam, Lacosamide and Ketamine as Adjunctive Treatment of Refractory Status Epilepticus
Status:
Withdrawn
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the efficacy and safety of levetiracetam , lacosamide
and ketamine treatment of refractory status epilepticus. This will be a randomized,
open-label, four-arm pilot study comparing time to cessation of refractory status
epilepticus, determined by continuous EEG monitoring, in patients with refractory status
epilepticus. Patients with status epilepticus who have been treated with standard dose
lorazepam (or midazolam) and ≥ 1000 mg phenytoin with documented levels of ≥20 mg/ml and
continue to have clinical status epilepticus for ≥1-24 hours after phenytoin loading will
receive intravenously (i.v.) either 4000 mg levetiracetam, 600 mg lacosamide (Group B), 2.5
mg/kg ketamine or phenobarbital 15 mg/kg phenobarbital (Group D)